Study details
Enrolling now
Rollover Trial for Povorcitinib
Incyte Corporation
NCT IDNCT06855498ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Target enrollment
600
Study length
about 3 years
Ages
18+
Locations
107 sites in AL, AR, AZ +24
What this study is about
Researchers are testing a treatment called povorcitinib in people who have already participated in other clinical trials of this drug. The trial will last about 1095 days and involve approximately 600 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take povorcitinib
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
kinase inhibitor
Endpoints
Primary: Proportion of participants with Treatment-Emergent Adverse Events (TEAEs)